|
SPRUCE BIOSCIENCES NOW ENROLLING CAHMELIA CLINICAL TRIALS
Spruce Biosciences, a late-stage clinical development company focused on developing and commercializing novel therapies for rare endocrine disorders, is now enrolling patients with classic CAH into the CAHmelia clinical trials.
The CAHmelia clinical program is designed to evaluate the efficacy of tildacerfont, an investigational, non-steroidal, oral, once-a-day corticotropin-releasing factor type-1 receptor antagonist, in two placebo-controlled, late-stage clinical studies in adults with classic CAH. In September 2019, Spruce Biosciences announced positive results from a Phase 2, multicenter, 12-week study of tildacerfont in adult patients with classic CAH.
“Our previous studies have demonstrated promising safety and efficacy results from the use of tildacerfont in adults with classic CAH,” said Richard King, Chief Executive Officer. “We are excited to move forward with the CAHmelia clinical program and encourage CAH patients and their families to visit CAHstudy.com to register their interest in the study and begin the screening process.
Interested individuals with classic CAH living in the United States are encouraged to visit CAHstudy.com to complete a short questionnaire and determine eligibility for participation in the CAHmelia clinical trials.
The CAHmelia clinical program is designed to evaluate the efficacy of tildacerfont, an investigational, non-steroidal, oral, once-a-day corticotropin-releasing factor type-1 receptor antagonist, in two placebo-controlled, late-stage clinical studies in adults with classic CAH. In September 2019, Spruce Biosciences announced positive results from a Phase 2, multicenter, 12-week study of tildacerfont in adult patients with classic CAH.
“Our previous studies have demonstrated promising safety and efficacy results from the use of tildacerfont in adults with classic CAH,” said Richard King, Chief Executive Officer. “We are excited to move forward with the CAHmelia clinical program and encourage CAH patients and their families to visit CAHstudy.com to register their interest in the study and begin the screening process.
Interested individuals with classic CAH living in the United States are encouraged to visit CAHstudy.com to complete a short questionnaire and determine eligibility for participation in the CAHmelia clinical trials.
SEE Frequently asked questions HERE
NADF is not endorsing the product, merely informing our members with CAH about a new clinical trial.
